Provider review, September 2026
Copergrine sells two entirely different things — peptide therapy and records software — and the only figures anywhere near its peptide page are the software's. A previous reading recorded those as the price of its peptide programme; they are not, and this row exists partly to correct that.
Copergrine does not publish a price today.
Copergrine also sells 3 compounds this site boards without publishing a price for them: BPC-157 (board ranks no provider), GHK-Cu and Ipamorelin (board ranks no provider).
Copergrine is not a paid partner; this link may earn a commission if that changes. Full disclosure.
The company runs a clinical service and a separate software product, and both are linked from the same navigation.
The figures on the peptide page sit in a block about plans and switching, next to migration costs and a savings calculator.
Read in context, they price the software per practitioner and per product line, on a first-term and a later rate.
Nothing on the page attaches any figure to a peptide, a vial, a month or a consultation.
Had those figures been recorded as the peptide price, this roster would carry a per-practitioner unit that exists nowhere else in it.
A unit nothing else on a comparison shares is a warning rather than a discovery, and it is worth treating as one.
Reading the surrounding sentence resolved it in one step: the words around the figures are about migrating records, not about therapy.
This row therefore publishes no price and says exactly why, which is more useful than a figure that would have been wrong.
The figures near this seller's peptide page belong to its records-software product, and nothing on the page attaches a figure to a peptide.
No certificate and no testing claim appear on any page read, in the text or in any attribute on it.
Publishing a figure somewhere on its own site is true of one hundred and thirty-seven of the two hundred and ten sellers here, so it separates far fewer of them than a reader expects.
The host itself was checked in the same pass as everything above: 404 at a nonsense path, same effective path, which is what any absence recorded here rests on.
One hundred and seventy-six of the two hundred and ten sellers here publish no state list at all, and this is one of them, so eligibility is settled inside an intake rather than before one.
Sixteen of the two hundred and ten sellers here name the facility that fills an order; this is one of the one hundred and ninety-four that do not, so there is no facility a reader can look up.
Four of the two hundred and ten sellers here describe lab work as included in what they charge, and this is not one of them.
It declares three of the sixteen compounds this site tracks, and eighty-one sellers here declare more, so it is a middling menu by the standards of this roster.
Auren Rx names both its prescribing group, Wasef Health, and its dispensing pharmacy, VialsRX in Houston, with street addresses and phone numbers, and lets a subscriber pause an auto-refill plan on NAD+, sermorelin, glutathione or GHK-Cu instead of forcing a full cancellation.
Auren Rx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Auren RxNo. The figures near the peptide page price a records-software product, on a per-practitioner basis with a first-term and a later rate.
Because a previous reading recorded them as the price of peptide therapy. Reading the surrounding words rather than matching the figures is what separates the two.
A named corporation, published in the footer of the product page itself.
Three that this site tracks.
No list is published; it describes itself as operating by telehealth nationwide.
Copergrine is not a paid partner; this link may earn a commission if that changes. Full disclosure.